Pfizer's COVID-19 vaccine has 'favourable safety profile', says US regulator

The FDA, however, also said that more research was needed to confirm evidence that the vaccine prevents even the worst cases of COVID-19, offers protection after the first of two doses and that the vaccine works for people who have previously been infected by the virus

Agence France-Presse December 08, 2020 21:54:24 IST
Pfizer's COVID-19 vaccine has 'favourable safety profile', says US regulator

A sign for the Food And Drug Administration is seen outside of the headquarters in White Oak, Maryland. AFP

Washington: The US Food and Drug Administration (FDA) issued a briefing document Tuesday saying the Pfizer-BioNTech COVID-19 vaccine is safe and effective, raising expectations the regulator is poised to grant emergency approval.

An independent committee advising the FDA will meet Thursday on the matter, after Britain became the first country to approve the vaccine last week.

Data from 38,000 US trial participants revealed "suggest a favorable safety profile, with no specific safety concerns identified that would preclude issuance of an EUA (emergency use authorisation)," the FDA document said.

It added that the vaccine's efficacy in preventing COVID-19 was 95 percent, worked uniformly across age groups, genders, and racial groups, as well as people with underlying conditions who are at high risk.

The FDA said more research was needed to confirm evidence that the vaccine prevents even the worst cases of COVID-19 , that it offers protection after the first of two doses and that it works for people previously been infected.

The companies have previously released some of their data in press statements but the FDA has access to a much more detail.

In a larger group of 43,000 volunteers which included additional adults and adolescents who signed up later, the most common side effects were injection site reactions (84 percent), fatigue (63 percent), headache (55 percent), muscle pain (38 percent), chills (31 percent), joint pain (23.6 percent), fever (14 percent).

Reactions graded as "severe" were more common after the second dose and less frequent in participants aged 55 and older.

There were some adverse events classed as "serious" — the highest grade — but there was no meaningful imbalance in the frequency these occurred in the vaccine and placebo arms.

There were four cases of Bell's palsy — a non-serious form of facial paralysis that generally resolves — in the vaccine group and none in the placebo group, but the document said this was in line with the frequency seen in the general population.

The advisory group will also consider what additional studies the manufacturers will need to undertake after issuance of an EUA.

Notably, the FDA is not in favour of immediately offering the vaccine to people in the placebo group, which is currently a heated area of discussion among the scientific community.

Updated Date:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

Tour de France champion Tadej Pogacar, UAE Emirates cycling team get COVID-19 vaccine
Sports

Tour de France champion Tadej Pogacar, UAE Emirates cycling team get COVID-19 vaccine

A total of 27 riders plus 32 staff of the UAE Emirates cycling team were vaccinated in Abu Dhabi.

India reports 14,545 new COVID-19 infections taking total over 1.06 cr; active cases below 1.89 lakh
Health

India reports 14,545 new COVID-19 infections taking total over 1.06 cr; active cases below 1.89 lakh

The COVID-19 toll as of Friday stands at 1,53,032 with 163 fatalities reported in the past 24 hours, said the Union health ministry

Aston Villa forced to close training ground after virus outbreak, FA Cup tie with Liverpool in jeopardy
Sports

Aston Villa forced to close training ground after virus outbreak, FA Cup tie with Liverpool in jeopardy

Aston Villa are the fourth Premier League side to be hit by a Covid-19 outbreak, adding to growing concerns over whether English football's top-flight can complete the season on schedule.